Maze Therapeutics (NASDAQ:MAZE) disclosed a set of insider transactions affecting a senior executive in a Form 4 filing with the Securities and Exchange Commission. Harold Bernstein, who serves as the company’s President of R&D and Chief Medical Officer, sold 15,000 shares of common stock on March 20, 2026, in a series of trades that together were valued at $736,439.
The sale prices reported ranged from $48.2027 to $50.0186 per share. The same filing shows Bernstein also exercised options to acquire 15,000 Maze Therapeutics common shares at an exercise price of $10.42, for a total cash outlay of $156,300. Those options formed part of an award that began vesting on October 3, 2023 and vested over time.
Following the combination of the option exercise and subsequent open-market sales, Bernstein is recorded as directly owning 0 shares of Maze Therapeutics.
Market context
Maze Therapeutics’ stock has seen a significant run-up over the past 12 months, increasing more than 300 percent. As of the data cited, the shares are trading at $47.99 with a market capitalization of $2.38 billion. Analysis from InvestingPro included in the filing commentary indicates the stock appears overvalued relative to its Fair Value estimate and has been placed among companies on a most-overvalued list.
The company is also scheduled to report its next quarterly results on April 6, 2026.
Analyst coverage and pipeline highlights
Recent analyst activity shows a cohort of research firms assigning positive ratings and issuing price targets for Maze Therapeutics. Truist Securities initiated coverage with a Buy rating and a price target of $68.00, calling out the company’s pipeline and singling out MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria as candidates engineered to potentially outperform competitors.
Mizuho also launched coverage, assigning an Outperform rating and a price target of $97.00. In its analysis, Mizuho emphasized Maze’s application of human genetic data and functional genomics through its Compass platform as a strategic strength. H.C. Wainwright reiterated a Buy rating with a $60.00 price target, referencing a perspective published in the Journal of the American Society of Nephrology that suggested a possible streamlined regulatory pathway for the company.
Together, these analyst actions reflect a degree of investor and research confidence in Maze Therapeutics’ strategic approach and clinical pipeline, even as valuation metrics draw cautionary attention.
Key takeaways
- Insider transaction: Harold Bernstein exercised 15,000 options at $10.42 and sold 15,000 shares on March 20, 2026, for $736,439 at prices between $48.2027 and $50.0186.
- Ownership update: After the transactions Bernstein directly holds 0 shares of Maze Therapeutics.
- Market and research context: Shares have risen over 300% in the past year, trade at $47.99, and carry a $2.38 billion market cap; multiple firms initiated or reiterated positive coverage while valuation screens flag the stock as overvalued relative to a Fair Value estimate.
Risks and uncertainties
- Valuation risk - Equity markets and valuation models indicate the stock is above its Fair Value estimate, which may affect investor expectations in the biotech and broader healthcare sectors.
- Earnings timing - The company is scheduled to report earnings on April 6, 2026, which could introduce volatility for MAZE shares around that date.
- Concentration of pipeline outcomes - Analyst support focuses on specific programs (MZE829, MZE782) and platform strengths; clinical or regulatory developments related to these programs could materially affect perceptions in biopharma markets.
This report is a factual account of the insider filing and recent analyst activity related to Maze Therapeutics. It notes the transactions, the existing market valuation assessments, and the research community’s recent ratings without inferring causes beyond the disclosed information.